Janssen Sciences Ireland Uc

This study gives HIV-1 patients ongoing access to the drug etravirine until they can switch to a local treatment option. It includes 180 participants aged 2 and older who previously benefited from etravirine in a parent trial. The main goal is to monitor safety by tracking any si…